Purpose: The focus of bariatric surgery is reduction of weight, reflected in body mass index (BMI). However, the resolution of comorbidity is a second important outcome indicator. The degree of comorbidity is hard to quantify objectively as comorbidities develop gradually and are interdependent. Multiple scoring systems quantifying comorbidity exist but they lack continuity and objectivity. In analogy with BMI as index for weight, the Metabolic Health Index (MHI) is developed as objective quantification of metabolic health status. Laboratory data were used as comorbidities affect biomarkers. Conversely, laboratory data can be used as objectively obtained variables to describe comorbidity.

Methods: Laboratory data were collected and crosschecked by national quality registry entries. Machine learning was applied to develop an ordinal logistic regression model, using 4 clinical and 32 laboratory input variables. The output was mathematically transformed into a continuous score for intuitive interpretation, ranging from 1 to 6 (MHI).

Results: In total, 4778 data records of 1595 patients were used. The degree of comorbidity is best described by age at phlebotomy, estimated Glomerular Filtration Rate (eGFR), and concentrations of glycated hemoglobin (HbA1c), triglycerides, and potassium. The model is independent of day of sampling and type of surgery. Mean MHI was significantly different between patient subgroups with increasing number of comorbidities.

Conclusion: The MHI reflects severity of comorbidity, enabling objective assessment of a bariatric patient's metabolic health state, regardless day of sampling and surgery type. Next to weight-focused outcome measures like %TWL, the MHI can serve as outcome measure for metabolic health.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11695-019-04244-1DOI Listing

Publication Analysis

Top Keywords

metabolic health
20
laboratory data
12
health mhi
8
degree comorbidity
8
day sampling
8
comorbidity
6
metabolic
5
mhi
5
mhi assessment
4
assessment comorbidity
4

Similar Publications

Erlotinib-induced Perioral Lesions Resembling Scleroderma.

Acta Dermatovenerol Croat

November 2024

Constantin A. Dasanu MD, PhD, Lucy Curci Cancer Center, Eisenhower Health, 39000 Bob Hope Dr, Rancho Mirage, CA 92270 , USA;

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is currently used in the therapy of several solid malignancies. This agent has been associated with several dermatological side-effects, the most common being papulo-pustular acneiform rash. Herein we describe a unique skin effect in a patient treated with erlotinib for non-small cell lung cancer.

View Article and Find Full Text PDF

Chemerin loss-of-function attenuates glucagon-like peptide-1 secretion in exercised obese mice.

Diabetes Obes Metab

January 2025

School of Exercise and Health, Shanghai Frontiers Science Research Base of Exercise and Metabolic Health, Shanghai University of Sport, Shanghai, China.

Aims: To investigate the role of chemerin reduction in mediating exercise-induced Glucagon-like peptide-1 (GLP-1) secretion and the amelioration of pancreatic β-cell function in obesity.

Materials And Methods: Obesity models were established using wild-type and chemerin systemic knockout mice, followed by 8 weeks of moderate-intensity continuous aerobic exercise training. Serum chemerin levels, GLP-1 synthesis, glucose tolerance, pancreatic β-cell function, structure, and apoptosis were assessed.

View Article and Find Full Text PDF

XGBoost-based nomogram for predicting lymph node metastasis in endometrial carcinoma.

Am J Cancer Res

December 2024

Department of Reproductive Medicine, The First Affiliated Hospital, Jinan University Guangzhou 510000, Guangdong, China.

This study aims to construct and optimize risk prediction models for lymph node metastasis (LNM) in endometrial carcinoma (EC) patients, thus improving the identification of patients at high risk of LNM and further providing accurate support for clinical decision-making. This retrospective analysis included 541 cases of EC treated at The First Affiliated Hospital, Jinan University between January 2017 and January 2022. Various clinical and pathological variables were incorporated, including age, body mass index (BMI), pathological grading, myometrial invasion, lymphovascular space invasion (LVSI), estrogen receptor (ER) and progesterone receptor (PR) levels, and tumor size.

View Article and Find Full Text PDF

Cardiac growth patterns and metabolism before and after birth in swine: Role of miR in proliferation, hypertrophy and metabolism.

J Mol Cell Cardiol Plus

September 2024

Early Origins of Adult Health Research Group, Health and Biomedical Innovation, UniSA: Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.

The adult mammalian heart is unable to undergo cardiac repair, limiting potential treatment options after cardiac damage. However, the fetal heart is capable of cardiac repair. In preparation for birth, cardiomyocytes (CMs) undergo major maturational changes that include exit from the cell cycle, hypertrophic growth, and mitochondrial maturation.

View Article and Find Full Text PDF

Dynamin-related protein 1 (Drp1) is a mitochondrial fission protein and a viable target for cardioprotection against myocardial ischaemia-reperfusion injury. Here, we reported a novel Drp1 inhibitor (DRP1i1), delivered using a cardiac-targeted nanoparticle drug delivery system, as a more effective approach for achieving acute cardioprotection. DRP1i1 was encapsulated in cubosome nanoparticles with conjugated cardiac-homing peptides (NanoDRP1i1) and the encapsulation efficiency was 99.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!